Biofrontera (BFRI) vs Radiopharm Theranostics (RADX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Biofrontera (BFRI) has outperformed Radiopharm Theranostics (RADX) over the past year, losing 28.4% versus a loss of 86.1%. Radiopharm Theranostics is the larger company by market cap ($9.9 million vs $9.5 million), about 1.0 times the size. Biofrontera converts more of its revenue into profit, with a net margin of -25.3% versus -1055.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BFRI | RADX |
|---|---|---|
| Share price | $0.53 | $0.6304 |
| Market cap | $9.51M | $9.90M |
| 1-day change | -7.02% | -9.71% |
| YTD return | -7.02% | -87.92% |
| 1-year return | -28.38% | -86.15% |
| 5-year return | -99.66% | — |
| Forward P/E | 1.32 | — |
| EPS (TTM) | $-0.26 | $-3.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $41.70M | $3.63M |
| Revenue growth (YoY) | +11.75% | +1114.27% |
| Net income (latest FY) | $-10.54M | $-38.34M |
| Gross margin | — | 1.08% |
| Operating margin | -27.21% | -1050.63% |
| Net margin | -25.26% | -1055.27% |
| 52-week high | $1.66 | $16.25 |
| 52-week low | $0.53 | $0.63 |
| Distance from 52-week high | -68.07% | -96.12% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +1032.08% | +2595.11% |
| Average volume | 429.04K | 55.23K |
| Shares outstanding | 17.95M | 15.70M |
| Employees | 84 | 14 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BFRI has outperformed RADX by 57.8 percentage points over the past year.
- Biofrontera is more profitable, keeping -25.3 cents of every revenue dollar as net income versus -1055.3 cents for Radiopharm Theranostics.
- Radiopharm Theranostics grew revenue faster in its latest fiscal year (+1114.27% vs +11.75%).
About Biofrontera
BFRI stock →Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. It offers Ameluz, BF-RhodoLED, RhodoLED XL lamp series, and RhodoLED Lamps, which are used for the treatment of actinic keratosis, which are pre-cancerous skin lesions.
Health Care · Biotechnology: Pharmaceutical Preparations · 84 employees
About Radiopharm Theranostics
RADX stock →Radiopharm Theranostics Limited a clinical-stage radiotherapeutics company, engages in the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas with high unmet medical needs. The company develops RAD101, a pivalate brain metastasis diagnostic; RAD102, a pivalate therapeutic; RAD201a, a Nano-mAb HER-2 breast diagnostic; RAD202, a Nano-mAb HER-2 breast therapeutic; RAD203, a Nano-mAb PDL1 non-small cell lung diagnostic; and RAD204, a Nano-mAb PDL1 non-small cell lung therapeutic.
Health Care · Biotechnology: Pharmaceutical Preparations · 14 employees
BFRI vs RADX FAQ
Which is bigger, Biofrontera or Radiopharm Theranostics?
Radiopharm Theranostics (RADX) is larger, with a market capitalization of $9.90M compared with $9.51M for Biofrontera (BFRI).
Which stock has performed better over the past year, BFRI or RADX?
BFRI returned -28.38% over the past 12 months, compared with -86.15% for RADX (price return, excluding dividends). Past performance does not predict future results.
Are Biofrontera and Radiopharm Theranostics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.